A citation-based method for searching scientific literature

Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Christopher E Nelson, Yaoying Wu, Matthew P Gemberling, Matthew L Oliver, Matthew A Waller, Joel D Bohning, Jacqueline N Robinson-Hamm, Karen Bulaklak, Ruth M Castellanos Rivera, Joel H Collier, Aravind Asokan, Charles A Gersbach. Nat Med 2019
Times Cited: 182



CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Yi-Li Min, Hui Li, Cristina Rodriguez-Caycedo, Alex A Mireault, Jian Huang, John M Shelton, John R McAnally, Leonela Amoasii, Pradeep P A Mammen, Rhonda Bassel-Duby, Eric N Olson. Sci Adv 2019
Times Cited: 114




List of shared articles



Times cited

Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives.
Mathilde Beaufils, Lauriane Travard, John Rendu, Isabelle Marty. Curr Pharm Des 2022
0

CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.
Lihong Guan, Yawei Han, Ciqing Yang, Suxiang Lu, Jiang Du, Han Li, Juntang Lin. Mol Neurobiol 2022
3

Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
Eman A Taha, Joseph Lee, Akitsu Hotta. J Control Release 2022
6

Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy.
Yasunari Matsuzaka, Yukihiko Hirai, Kazuo Hashido, Takashi Okada. Int J Mol Sci 2022
0

CRISPR Therapeutics for Duchenne Muscular Dystrophy.
Esra Erkut, Toshifumi Yokota. Int J Mol Sci 2022
0

CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Cedric Happi Mbakam, Gabriel Lamothe, Guillaume Tremblay, Jacques P Tremblay. Neurotherapeutics 2022
2

Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.
Dileep R Karri, Yu Zhang, Francesco Chemello, Yi-Li Min, Jian Huang, Jiwoong Kim, Pradeep P A Mammen, Lin Xu, Ning Liu, Rhonda Bassel-Duby,[...]. Mol Ther Nucleic Acids 2022
0

CRISPR Modeling and Correction of Cardiovascular Disease.
Ning Liu, Eric N Olson. Circ Res 2022
1

Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing.
Qiubing Chen, Ying Zhang, Hao Yin. Adv Drug Deliv Rev 2021
12

Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Tejal Aslesh, Esra Erkut, Toshifumi Yokota. Expert Opin Biol Ther 2021
3

Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Britt Hanson, Matthew J A Wood, Thomas C Roberts. RNA Biol 2021
12

Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy.
Vratko Himič, Kay E Davies. Eur J Hum Genet 2021
11

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy.
Fernanda Fortunato, Rachele Rossi, Maria Sofia Falzarano, Alessandra Ferlini. J Clin Med 2021
15

Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression.
Eleonora Maino, Daria Wojtal, Sonia L Evagelou, Aiman Farheen, Tatianna W Y Wong, Kyle Lindsay, Ori Scott, Samar Z Rizvi, Elzbieta Hyatt, Matthew Rok,[...]. EMBO Mol Med 2021
5

CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Eunyoung Choi, Taeyoung Koo. Mol Ther 2021
7

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
F Chemello, A C Chai, H Li, C Rodriguez-Caycedo, E Sanchez-Ortiz, A Atmanli, A A Mireault, N Liu, R Bassel-Duby, E N Olson. Sci Adv 2021
27

Toward the correction of muscular dystrophy by gene editing.
Eric N Olson. Proc Natl Acad Sci U S A 2021
13

Efficient precise in vivo base editing in adult dystrophic mice.
Li Xu, Chen Zhang, Haiwen Li, Peipei Wang, Yandi Gao, Nahush A Mokadam, Jianjie Ma, W David Arnold, Renzhi Han. Nat Commun 2021
15

Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy.
Theresa M Raimondo, David J Mooney. Sci Adv 2021
8

Gene editing and modulation for Duchenne muscular dystrophy.
Anthony A Stephenson, Kevin M Flanigan. Prog Mol Biol Transl Sci 2021
2

A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
Yu Zhang, Takahiko Nishiyama, Hui Li, Jian Huang, Ayhan Atmanli, Efrain Sanchez-Ortiz, Zhaoning Wang, Alex A Mireault, Pradeep P A Mammen, Rhonda Bassel-Duby,[...]. Mol Ther Methods Clin Dev 2021
3

CRISPR/Cas correction of muscular dystrophies.
Yu Zhang, Takahiko Nishiyama, Eric N Olson, Rhonda Bassel-Duby. Exp Cell Res 2021
2

Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy.
Shagun Singh, Tejpal Singh, Chaitanya Kunja, Navdeep S Dhoat, Narender K Dhania. Eur J Pharmacol 2021
0

Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Jia Li, Kaiying Wang, Yuchen Zhang, Tuan Qi, Juanjuan Yuan, Lei Zhang, Han Qiu, Jinxi Wang, Huang-Tian Yang, Yi Dai,[...]. Circulation 2021
3


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy